Clicky

Novavax, Inc.(NVAX)

Description: Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.


Keywords: Medicine Biopharmaceutical Infectious Diseases Vaccines Clinical Development Influenza Vaccination Coronavirus Rabies Influenza Vaccine Seasonal Influenza Novavax

Home Page: www.novavax.com

NVAX Technical Analysis

21 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240 268 2000


Officers

Name Title
Mr. Stanley Charles Erck Pres, CEO & Director
Mr. James Patrick Kelly C.F.A. Exec. VP, CFO & Treasurer
Mr. John A. Herrmann III Exec. VP, Chief Legal Officer & Corp. Sec.
Mr. John Joseph Trizzino B.S., M.B.A. Exec. VP and Chief Bus. & Commercial Officer
Dr. Gregory M. Glenn Pres of R&D
Mr. Richard P. Crowley Exec. VP & COO
Dr. Gale E. Smith Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
Mr. Biegie Lee Sr. VP & Chief Information Officer
Mr. Troy Morgan Esq., J.D. Sr. VP & Chief Compliance Officer
Ms. Erika S. Trahan Associate Director of Investor & PR

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0.5781
Trailing PE: 0
Price-to-Book MRQ: 49.522
Price-to-Sales TTM: 0.4812
IPO Date: 1995-12-05
Fiscal Year End: December
Full Time Employees: 1541
Back to stocks